Condition
Pulmonary Carcinoid Tumor
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results75% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (4)
Trial Status
Completed3
Withdrawn1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04915144Phase 2Withdrawn
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
NCT02259725Phase 2Completed
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
NCT00093782Phase 2Completed
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
NCT00084461Phase 2Terminated
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT00004074Phase 1Completed
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Showing all 5 trials